Skip to content
Study details
Enrolling now

Multi-Center PAMPA Study

NYU Langone Health
NCT IDNCT05004727ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

176

Study length

about 6.5 years

Ages

18+

Locations

3 sites in MA, NY

What this study is about

This trial is testing guselkumab, a treatment for psoriasis, compared to a placebo. The goal is to see if guselkumab can reduce inflammation and prevent the development of psoriatic arthritis (PsA) in people with high-risk psoriasis.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Guselkumab
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

guselkumab

Drug routes

injection, intravenous

Endpoints

Primary: Change in Musculoskeletal, Power Doppler Ultrasound (MSK-PDUS) Composite Score

Secondary: Change in EuroQol-5D (EQ-5D) Score, Change in Ultrasound (US) Score, Change in the ultrasound composite score of synovitis

Body systems

Dermatology